Navigation Links
Chembio Reports 3rd Quarter 2011 Results
Date:11/3/2011

ion) than the gross margin dollars in the comparable period in 2010.  Product gross margin increased by $.79 million, or 52.7% ($2.28 million vs. $1.49 million), over the comparable period in 2010.
  • Research and development expenses remained nearly constant compared to the 2010 period.  The mix of items did change, for instance an increase in clinical trials of $61,000 was partially offset by a decrease in materials of $58,000.
  • Selling General & Administrative Expenses increased in the third quarter of 2011 by $147,000 over the comparable third quarter of 2010.  An increase in commissions, due to the higher DPP product sales to Brazil, as well as increases in wages, share-based compensation and other expenses, partially offset by decreased professional fees was responsible for the increase.
  • Operating income was approximately $.48 million in the third quarter of 2011 as compared to operating income in the third quarter of 2010 of approximately $.18 million. In addition, net income was approximately $.48 million in the third quarter of 2011 as compared to a net income in the third quarter of 2010 of approximately $.17 million.

  • Financial Highlights for the nine months ended September 30, 2011

  • Product sales for the nine months ended September 30, 2011 increased 38% to $11.52 million from $8.34 million in the same period of 2010.
  • R&D, milestone and grant revenues for the nine months decreased to $1.53 million from $2.30 million in the same period of 2010, and license and royalty revenue decreased to $.13 million from $.40 million.  
  • The increased product revenue, together with changes in product mix, partially offset by decreased R&D and licensing and royalty revenues, combined to produce gross margin dollars that were $1.04 million, or 18.5%, greater ($6.65 million vs. $5.61 million) than the gross margin dollars in the comparable period in 2010.  Product gross margi
    '/>"/>

  • SOURCE Chembio Diagnostics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Chembio to Host Conference Call to Discuss 3rd Quarter 2011 Financial Results
    2. Chembio Diagnostics CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News
    3. NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
    4. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
    5. CVS Caremark Reports Third Quarter Results
    6. Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
    7. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
    8. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
    9. Par Pharmaceutical Companies Reports Third Quarter 2011 Results
    10. Luminex Corporation Reports Third Quarter 2011 Results
    11. Anthera Pharmaceuticals Reports 2011 Third Quarter Financial Results and Operational Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/2/2015)... , July 2, 2015 Numotion,s Board of ... announced that Tamas Feitel has joined the ... Numotion after a highly successful 18 year career at ... driving strategy, profitability, and productivity to result in significant ... position was Chief Financial Officer for GE Healthcare Global ...
    (Date:7/2/2015)... 2, 2015   Decision Resources Group ... identify less frequent dosing as the highest unmet ... the burden on both patients and providers associated ... (VEGF) injections, which are the current standard of ... which is in development for dosing every two ...
    (Date:7/2/2015)... , July 2, 2015 ... (Homofermentative & Heterofermentative), Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes ... and Forecast to 2020", Silage Inoculants & Enzymes Market ... a CAGR of 4.0% from 2015 to 2020. ... igures spread through 194 P ...
    Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4
    ... Sept. 1 There has been recent,concern that ... Montelukast is a Food and Drug Administration (FDA) ... than a decade for the treatment of,asthma and ... the,American Lung Association has found no evidence of ...
    ... CMS, Inc., an Elekta Company and,worldwide ... management,solutions, today announced that three sites have ... Modulated,Radiotherapy (IMRT) treatment planning system. Allegheny General ... Rotterdam,Netherlands, and Froedtert Memorial Lutheran Hospital in ...
    Cached Medicine Technology:American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 2American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 3CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System 2
    (Date:7/4/2015)... ... July 04, 2015 , ... Tyler Boden, Project ... technical sales expertise from the North American Board of Certified Energy Practitioners (NABCEP®), ... most highly respected and well established national certification organization for renewable energy professionals. ...
    (Date:7/3/2015)... ... July 03, 2015 , ... ... on July 2nd creating a buzz of media attention. In an effort to ... by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling overwhelmed by ...
    (Date:7/3/2015)... ... July 03, 2015 , ... ... 2015 Annual Conference , the premiere continuing education and networking event ... at SeaWorld in Orlando, Florida. Speakers include the leading rheumatology experts in ...
    (Date:7/3/2015)... ... July 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Dallas Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 ... the Westin Galleria Dallas. , Designed to take participants from the basic training and ...
    (Date:7/3/2015)... Lenexa, KS (PRWEB) , ... July 03, 2015 ... ... firm dedicated exclusively to healthcare providers, has been retained to lead a national ... Okla. One of the top-ranked executive search firms in the healthcare industry, B. ...
    Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3
    ... smoking the first cigarette in the morning, the more difficult ... Yale School of Medicine study in Drug and Alcohol Dependence. ... found significant reductions in craving, withdrawal and mood after smoking ... reduction, the more likely the smoker would relapse, said Benjamin ...
    ... patients of the superbug MRSA - by treating their foot ... his team used green bottle fly larvae to treat 13 ... found all but one were cured within a mean period ... the conventional treatment. ,Professor Boulton, who published the ...
    ... developing a brain disease similar to mad cow disease, according ... Academy of Neurology's 59th Annual Meeting in Boston, April 28 ... cow disease, and chronic wasting disease, are fatal and there ... when an animal eats the body parts of other animals ...
    ... made headway in the development of an investigative blood ... to develop complications in the bone marrow, leading to ... Brisbane's Mater Medical Research Institute (MMRI) and Sydney's West ... a simple blood test to detect such tendencies. ...
    ... companies is not happy with the proposal to fortify all ... the state and federal governments to veto this proposal. ... enhance the foliate levels in women of child-bearing age. The ... spina bifida. ,If you ask Ian Greenshields from ...
    ... both get high blood pressure and related kidney disease, the path ... men , researchers say. ,They may end up ... could be very different, says Dr. Jennifer C. Sullivan, pharmacologist/physiologist ... ,Its known that men tend to develop hypertension earlier ...
    Cached Medicine News:Health News:Reduction in Nicotine Craving Predicts Ability to Quit 2Health News:Maggots Rid Patients of MRSA 2Health News:Vaccine Prevents Prion Disease in Mice 2Health News:Cause of Gender Differences in Blood Pressure, Kidney Damage Under Study 2Health News:Cause of Gender Differences in Blood Pressure, Kidney Damage Under Study 3
    McIntyre-Binkhorst Cannula have a smooth blunt tip end opening....
    Army navy retractor set....
    Sharp. 4 mm wide. Hand-Held...
    Adsons bayonet forceps....
    Medicine Products: